---
title: "Ile zap\u0142acicie za transakcj\u0119 w honorariach?"
description: "Honoraria w transakcjach ameryka\u0144skich, a nie ceny zakupu: doradztwo, prawo, debiut, plasowanie i Chapter 11."
site: Deal Cost Index
content_updated: 2026-10-29
license: CC BY 4.0
html: https://dealcostindex.com/index-pl.html
---
Honoraria w transakcjach amerykańskich

# Ile zapłacicie za transakcję w honorariach?

Deal Cost Index mierzy, ile firmy płacą bankom inwestycyjnym, prawnikom, audytorom, bankom plasującym i dostawcom data roomów za doprowadzenie transakcji do końca. Ceny zakupu, mnożniki wyceny i koszt finansowania nie są przedmiotem tej strony.

Wprowadźcie parametry transakcji, aby oszacować koszty doradztwa, prawne, księgowe, due diligence i data roomu. Każda pozycja jest wyliczona z dokumentów publicznych, opublikowanych badań albo cenników dostawców i odsyła do swojego źródła.

Zbudowane z

660

dokumentów połączeniowych i ofert przejęcia

502

prospektów debiutów

52,571

emisji prywatnych (Form D)

47

postępowań Chapter 11

132

opublikowanych wartości z badań

Dokumenty złożone w SEC i w amerykańskich sądach upadłościowych, 2023–2026.

Szacowane honoraria

$4.4M–$10.7M — Sprzedaż (strona sprzedającego) · $250M

- M&A advisor fees 93%

- Deal counsel 5%

- Sell-side quality of earnings 2%

- Virtual data room <1%

Suma 4 pozycji oznaczonych jako uwzględnione, wyliczona z dokumentów publicznych, opublikowanych badań i cenników dostawców. Pozycje na szaro podano dla odniesienia i nie wchodzą do sumy.

To szacunek, nie wycena. Ten przedział wynika z publicznie dostępnych informacji o innych transakcjach. Honoraria w waszej transakcji będą zależeć od jej okoliczności, od wybranych firm i od tego, co wynegocjujecie. Nic tutaj nie jest doradztwem finansowym, prawnym, podatkowym ani inwestycyjnym. [Warunki i zastrzeżenie](https://dealcostindex.com/terms.html)

continues to $25M →

$0$9.16M

| Pozycja | Środkowa połowa i mediana | Przedział |
|---|---|---|
| M&A advisor fees (all target-side advisors)Filed 58 rekordyTotal target-side advisor fees as a share of deal value in 58 disclosed deals ($125M–$500M): median 2.60%, middle half 1.73%–3.66%. Public-target deals; private deals of this size usually pay at least as much. |  | $4.32M–$9.16Mmediana $6.5M |
| Fairness opinion fee (part of the advisor fee)Filed 45 rekordy · Tylko dla odniesieniaPortion payable on delivery of the opinion, from the same filings. Usually credited against the success fee. |  | $1M–$1.75Mmediana $1M |
| Lehman / Double Lehman formulaFormula · Tylko dla odniesienia5-4-3-2-1 and 10-8-6-4-2 schedules applied to $250M. Shown for reference; this is not an observed fee. |  | $2.6M–$5.2Mmediana $3.9M |
| Monthly retainerSurvey · Tylko dla odniesienia$5,000–$10K a month is the most common retainer, over 6 months; most advisors credit it against the success fee. [Firmex 2025](https://4804905.fs1.hubspotusercontent-na1.net/hubfs/4804905/Firmex-MAFeeGuide-Global-25.pdf) |  | $30K–$60Kmediana $45K |
| Deal counselSurveyExternal legal spend per M&A deal reported by US private equity firms (average $353K, range $50K–$1M, 2020 data). Large-firm partners in New York averaged $1,972/hour in H1 2025. [Apperio 2020](https://www.persuit.com/learn/typical-manda-deals-cost-us-private-equity-353k-in-legal-spend-and-other-outside-counsel-statistics-from-us-based-pe-firms) [Wolters Kluwer ELM Solutions via B 2025](https://www.nasdaq.com/press-release/wolters-kluwer-study-sets-stage-2026-sharp-contrasts-regional-law-firm-rates-and) |  | $50K–$1Mmediana $353K |
| Sell-side quality of earningsSurveyPublished price ranges for a >$150M deal: boutique providers $25K–$50K, buy-side QoE $150K–$400K, sell-side priced 10–30% higher. [BD Emerson 2026](https://www.bdemerson.com/article/quality-of-earnings-report-cost) [Bedrock Quality of Earnings 2026](https://www.bedrockqoe.com/insights/quality-of-earnings-report-cost) |  | $25K–$520Kmediana $114K |
| Virtual data roomList price 8 rekordyMiddle half of list-price totals from 8 vendors whose published plans cover 20 GB and 2 admins for 6 months, billed monthly where offered. Plans are priced for the months billed, not the months used. [How data room totals are calculated](https://dealcostindex.com/vdr.html#billing-basis) |  | $2,499–$18Kmediana $3,764 |
| R&W insuranceSurvey · Tylko dla odniesieniaLimit 10% of EV ($25M) × rate on line 2–3.5% (Q4 2025 average 3.23%), plus underwriting fee and up to 6% surplus lines tax. [Gallagher 2025](https://www.ajg.com/-/media/files/gallagher/us/news-and-insights/2025/transactional-risk-2025-review-and-2026-outlook.pdf) [Vanbridge 2024](https://www.vanbridge.com/wp-content/uploads/2024/02/2024-Vanbridge-Reps-and-Warranties-Reference-Guide.pdf) [Vanbridge 2024](https://www.vanbridge.com/wp-content/uploads/2024/02/2024-Vanbridge-Reps-and-Warranties-Reference-Guide.pdf) Typically paid by the buyer; sometimes split. |  | $535K–$978Kmediana $850K |
| Escrow held back (not a fee)Survey · Tylko dla odniesieniaCash withheld from proceeds, typically released after ~12 months: median 2.8% of deal value with R&W insurance, 10% without. [DealLawyers.com 2026](https://www.deallawyers.com/blog/2026/04/study-private-target-deal-terms-10.html) [SRS Acquiom 2025](https://www.srsacquiom.com/our-insights/ma-deals/) Typically paid by the buyer; sometimes split. |  | $7M–$25Mmediana $7M |
| Razem |  | $4.4M–$10.7MSuma median $6.97M |

Podstawa każdej pozycji, noty pod nią oraz tabele wykorzystanych transakcji porównywalnych pozostają w języku angielskim: cytują i streszczają dokumenty, z których pochodzą, a cytatów ta strona nie tłumaczy. Wiążąca jest angielska wersja tej strony.

## Public-company deals used ($125M–$500M)

Each fee is taken from the filing; hover over a fee to see the sentence it comes from. Deal values marked “computed” are the cash price per share multiplied by shares outstanding.

| Target | Deal value | Advisor | Fee | % of value | Source |
|---|---|---|---|---|---|
| Greenbacker Renewable Energy | $375M — stated | Wells Fargo Securities | $7M | 1.87% | [DEFM14A Oct 2026](https://www.sec.gov/Archives/edgar/data/1563922/000175392626001969/g085989_defm14a.htm) |
| Nathans Famous, Inc. | $418M — computed | Jefferies | $9.6M | 2.30% | [DEFM14A Sep 2026](https://www.sec.gov/Archives/edgar/data/69733/000110465926110393/tm267612-2_defm14a.htm) |
| Luxfer Holdings PLC | $465M — computed | Deutsche Bank | $8M | 1.72% | [DEFM14A Sep 2026](https://www.sec.gov/Archives/edgar/data/1096056/000207709626000260/ea0303080-02.htm) |
| AstroNova, Inc. — acquired by Arcline | $225M — computed | Rockefeller | $4.2M | 1.87% | [DEFM14A Jul 2026](https://www.sec.gov/Archives/edgar/data/8146/000119312526326441/d140981ddefm14a.htm) |
| Simulations Plus, Inc. | $375M — stated | Morgan Stanley | $11M | 2.93% | [DEFM14A Jul 2026](https://www.sec.gov/Archives/edgar/data/1023459/000102345926000051/defm14a.htm) |
| Open Lending Corp — acquired by Anv | $236M — computed | FT | $8.7M | 3.68% | [SC 14D9 Jun 2026](https://www.sec.gov/Archives/edgar/data/1806201/000119312526286952/d140679dsc14d9.htm) |
| Cross Country Healthcare Inc. | $428M — computed | BofA Securities | $6.12M | 1.43% | [DEFM14A Jun 2026](https://www.sec.gov/Archives/edgar/data/1141103/000114036126025249/ny20073866x2_defm14a.htm) |
| XOMA Royalty Corp | $489M — computed | Leerink Partners | $18.4M | 3.76% | [DEFM14A Jun 2026](https://www.sec.gov/Archives/edgar/data/791908/000119312526266069/d137792ddefm14a.htm) |
| Sun Country Airlines Holdings, Inc. — acquired by Allegiant | $218M — computed | Goldman Sachs | $22.6M | 10.36% | [DEFM14A Mar 2026](https://www.sec.gov/Archives/edgar/data/1743907/000114036126012383/ny20068391x1_defm14a.htm) |
| Calavo Growers, Inc. — acquired by Mission Produce | $486M — stated | Jefferies | $12.5M | 2.57% | [DEFM14A Mar 2026](https://www.sec.gov/Archives/edgar/data/1133470/000119312526117814/d15959ddefm14a.htm) |
| Diamond Hill Investment Group, Inc. — acquired by First Eagle | $430M — computed | Broadhaven | $7M | 1.63% | [DEFM14A Jan 2026](https://www.sec.gov/Archives/edgar/data/909108/000114036126002681/ny20061565x2_defm14a.htm) |
| Crawford United Corporation — acquired by Spx | $300M — stated | Lake StreetStout | $2.4M | 0.80% | [DEFM14A Jan 2026](https://www.sec.gov/Archives/edgar/data/47307/000143774926000391/crawa20260103_defm14a.htm) |
| TrueCar, Inc. | $227M — computed | Morgan Stanley | $12.5M | 5.51% | [DEFM14A Nov 2025](https://www.sec.gov/Archives/edgar/data/1327318/000110465925115451/tm2528639-6_defm14a.htm) |
| WideOpenWest, Inc. — acquired by DigitalBridge and Crestview | $290M — stated | Centerview Partners | $19.4M | 6.69% | [DEFM14A Oct 2025](https://www.sec.gov/Archives/edgar/data/1701051/000110465925102255/tm2523589-7_defm14a.htm) |
| scPharmaceuticals Inc. | $285M — computed | Leerink Partners | $8.8M | 3.09% | [SC 14D9 Sep 2025](https://www.sec.gov/Archives/edgar/data/1604950/000119312525225023/d846289dsc14d9a.htm) |
| Potbelly Corporation — acquired by RaceTrac | $409M — computed | Piper Sandler | $6.9M | 1.69% | [SC 14D9 Sep 2025](https://www.sec.gov/Archives/edgar/data/1195734/000119312525213634/d936677dsc14d9.htm) |
| scPharmaceuticals Inc. | $285M — computed | Leerink Partners | $8.8M | 3.09% | [SC 14D9 Sep 2025](https://www.sec.gov/Archives/edgar/data/1604950/000119312525198383/d152074dsc14d9.htm) |
| Y-mAbs Therapeutics, Inc. — acquired by Serb | $354M — computed | Centerview Partners | $9.1M | 2.57% | [SC 14D9 Aug 2025](https://www.sec.gov/Archives/edgar/data/1722964/000110465925079582/tm2523645-2_sc14d9.htm) |
| DallasNews Corp | $150M — computed | J.P. Morgan | $5M | 3.34% | [DEFM14A Aug 2025](https://www.sec.gov/Archives/edgar/data/1413898/000119312525181885/d24897ddefm14a.htm) |
| iTeos Therapeutics, Inc. | $385M — computed | TD Cowen | $9.5M | 2.47% | [SC 14D9 Aug 2025](https://www.sec.gov/Archives/edgar/data/1808865/000119312525170952/d854787dsc14d9.htm) |
| CARGO Therapeutics, Inc. | $202M — computed | TD Cowen | $4.3M | 2.13% | [SC 14D9 Jul 2025](https://www.sec.gov/Archives/edgar/data/1966494/000119312525163464/d78481dsc14d9.htm) |
| Sage Therapeutics, Inc. — acquired by Supernus Pharmaceuticals | $452M — computed | Goldman Sachs | $14.7M | 3.25% | [SC 14D9 Jul 2025](https://www.sec.gov/Archives/edgar/data/1597553/000119312525155020/d63256dsc14d9.htm) |
| Verve Therapeutics, Inc. — acquired by Eli Lilly and Company | $267M — computed | Centerview PartnersGuggenheim Securities | $33.7M | 12.60% | [SC 14D9 Jun 2025](https://www.sec.gov/Archives/edgar/data/1840574/000119312525146127/d917975dsc14d9.htm) |
| PHX Minerals Inc. — acquired by WhiteHawk Energy | $162M — computed | RBCCMIntrepid | $4.25M | 2.62% | [SC 14D9 May 2025](https://www.sec.gov/Archives/edgar/data/315131/000110465925051830/tm2515778-1_sc14d9.htm) |
| Checkpoint Therapeutics, Inc. — acquired by Sun Pharmaceutical Industries (LW Securities engaged) | $475M — computed | Kroll | $400K | 0.08% | [DEFM14A Apr 2025](https://www.sec.gov/Archives/edgar/data/1651407/000110465925038082/tm252489-4_defm14a.htm) |
| Akoya Biosciences, Inc. — acquired by Quanterix Corporation | $199M — computed | Perella Weinberg Partners | $3.5M | 1.76% | [DEFM14A Apr 2025](https://www.sec.gov/Archives/edgar/data/1711933/000110465925035134/tm2510802-1_defm14a.htm) |
| 2seventy bio, Inc. — acquired by Bristol-Myers Squibb | $262M — computed | Goldman Sachs | $8.58M | 3.28% | [SC 14D9 Apr 2025](https://www.sec.gov/Archives/edgar/data/1860782/000114036125013644/ny20046860x1_sc14d9.htm) |
| Logility Supply Chain Solutions, Inc — acquired by Aptean | $478M — computed | Lazard | $9.8M | 2.05% | [DEFM14A Mar 2025](https://www.sec.gov/Archives/edgar/data/713425/000114036125006872/ny20042527x2_defm14a.htm) |
| Poseida Therapeutics, Inc. | $390M — computed | Centerview Partners | $25.5M | 6.54% | [SC 14D9 Dec 2024](https://www.sec.gov/Archives/edgar/data/1661460/000119312524286056/d871087dsc14d9a.htm) |
| Poseida Therapeutics, Inc. — acquired by Roche | $390M — computed | Centerview Partners | $25.5M | 6.54% | [SC 14D9 Dec 2024](https://www.sec.gov/Archives/edgar/data/1661460/000119312524273550/d901928dsc14d9.htm) |
| Universal Stainless & Alloy Products Inc | $456M — stated | TD Cowen | $8.1M | 1.78% | [DEFM14A Nov 2024](https://www.sec.gov/Archives/edgar/data/931584/000119312524267249/d842335ddefm14a.htm) |
| ARC Document Solutions, Inc. | $162M — stated | William Blair | $1M | 0.62% | [DEFM14A Oct 2024](https://www.sec.gov/Archives/edgar/data/1305168/000114036124043469/ny20035563x8_defm14a.htm) |
| Iteris, Inc. — acquired by Almaviva | $308M — computed | Morgan Stanley | $10.5M | 3.41% | [DEFM14A Sep 2024](https://www.sec.gov/Archives/edgar/data/350868/000114036124041589/ny20034699x2_defm14a.htm) |
| G1 Therapeutics, Inc. | $259M — computed | Centerview PartnersGuggenheim Securities | $16.9M | 6.54% | [SC 14D9 Aug 2024](https://www.sec.gov/Archives/edgar/data/1560241/000119312524203615/d856692dsc14d9.htm) |
| Desktop Metal, Inc. | $349M — computed | Stifel | $4.2M | 1.20% | [DEFM14A Aug 2024](https://www.sec.gov/Archives/edgar/data/1754820/000110465924089909/tm2420443-3_defm14a.htm) |
| The Aaron's Company, Inc. — acquired by Iqv | $310M — computed | J.P. Morgan | $10.1M | 3.26% | [DEFM14A Aug 2024](https://www.sec.gov/Archives/edgar/data/1821393/000119312524199465/d816734ddefm14a.htm) |
| Alimera Sciences, Inc. | $498M — computed | Perella Weinberg PartnersCenterview Partners | $18M | 3.62% | [DEFM14A Aug 2024](https://www.sec.gov/Archives/edgar/data/1267602/000110465924087307/tm2419772-3_defm14a.htm) |
| SilverBow Resources, Inc. — acquired by Crescent | $391M — computed | BofA SecuritiesEvercore | $32M | 8.18% | [DEFM14A Jun 2024](https://www.sec.gov/Archives/edgar/data/351817/000162828024030396/silverbow-defm14a.htm) |
| Whole Earth Brands, Inc. — acquired by Sababa | $211M — computed | JefferiesCiti | $13M | 6.17% | [DEFM14A Jun 2024](https://www.sec.gov/Archives/edgar/data/1753706/000114036124031141/ny20024121x13_defm14a.htm) |
| Transphorm, Inc. — acquired by Renesas | $323M — computed | BofA Securities | $6.21M | 1.92% | [DEFM14A Mar 2024](https://www.sec.gov/Archives/edgar/data/1715768/000119312524058005/d585789ddefm14a.htm) |

Showing 40 of 58, most recent first. The full list is on the dataset page.

## Zbiory danych

- [660Honoraria doradców M&ADokumenty połączeniowe i oferty przejęcia, 2023–2026. Honoraria według wielkości transakcji, poziomu firmy, branży i zleceniodawcy, część płatna przy zamknięciu oraz profil każdego często występującego banku.](https://dealcostindex.com/ma-advisor-fees-pl.html)

- [288Koszty prawneKancelarie przy debiutach, połączeniach i postępowaniach Chapter 11: koszty prawne debiutu, stawki godzinowe partnerów i profil każdej często występującej kancelarii.](https://dealcostindex.com/legal-fees-pl.html)

- [86Koszty księgoweAudytorzy amerykańskich debiutów i koszty księgowe wyszczególnione przez emitentów, ceny badań jakości zysków oraz profil każdej często występującej firmy audytorskiej.](https://dealcostindex.com/accounting-fees-pl.html)

- [502Koszty debiutu giełdowegoProspekty ostateczne. Prowizja za plasowanie oraz wyszczególnione koszty prawne, księgowe, druku i wprowadzenia do obrotu.](https://dealcostindex.com/ipo-costs-pl.html)

- [52,571Prowizje za plasowanieEmisje prywatne z formularzy Form D, od 2023 Q1 do 2026 Q3. Prowizje i wynagrodzenia pośredników według wielkości, instrumentu i branży.](https://dealcostindex.com/capital-raise-fees-pl.html)

- [47Wynagrodzenia w Chapter 11Akta sądowe. Wynagrodzenia miesięczne, wynagrodzenia za restrukturyzację i stawki godzinowe doradców dłużnika.](https://dealcostindex.com/restructuring-fees-pl.html)

- [132Due diligence, ubezpieczenie i escrowOpublikowane badania i cenniki firm dla kosztów, których dokumenty nie ujawniają transakcja po transakcji.](https://dealcostindex.com/diligence-insurance-pl.html)

- [25Data roomyCeny z cenników, szacunki podmiotów trzecich i deklarowane certyfikaty, wyliczone dla waszego data roomu.](https://dealcostindex.com/vdr-pl.html)

- [639Katalog doradcówBanki, kancelarie i audytorzy z 27 list publicznych, podstawa każdego poziomu w kalkulatorze.](https://dealcostindex.com/providers-pl.html)

## Jak cytować indeks

Cytujcie wykorzystaną stronę jako Deal Cost Index, „<tytuł strony>”, wersja danych 2026.10.3, z odnośnikiem. Dane źródłowe udostępniono na licencji [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/) i można je pobrać w formacie CSV ze [strony metodologii](https://dealcostindex.com/methodology-pl.html); każdy wiersz zachowuje odnośnik do dokumentu lub publikacji, z której pochodzi.

Deal Cost Index. Data: CC BY 4.0.